Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: A large, patient- and rater-blinded, randomized, controlled study
John F. Greden(Pine Rest Christian Mental Health Services), Bryan Dechairo(Myriad (Germany)), Sagar V. Parikh(University of Michigan), Charles DeBattista, Charles R. Conway(John Cochran VA Medical Center), Boadie W. Dunlop(Emory University), Anthony J. Rothschild(UMass Memorial Health Care), Michael E. Thase(Veterans Health Administration), Michael Jablonski, James Li, Richard C. Shelton(University of Alabama at Birmingham), Francis M. Mondimore(Johns Hopkins University), Krystal Brown(Myriad Genetics), Lindsey Burns, Brent P. Forester(Tufts Medical Center), Matthew Macaluso(University of Kansas)
Cited by 346
Related Papers
The 16-Item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression
|Biological Psychiatry|2003|3.9k
Canadian Network for Mood and Anxiety Treatments (<scp>CANMAT</scp>) and International Society for Bipolar Disorders (<scp>ISBD</scp>) 2018 guidelines for the management of patients with bipolar disorder
|Bipolar Disorders|2018|1.8k
A Comparison of Nefazodone, the Cognitive Behavioral-Analysis System of Psychotherapy, and Their Combination for the Treatment of Chronic Depression
|New England Journal of Medicine|2000|1.3k
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013
|Bipolar Disorders|2012|1.2k
Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder
|The Canadian Journal of Psychiatry|2016|1.1k